279 related articles for article (PubMed ID: 31563013)
1. Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
Schepetkin IA; Karpenko AS; Khlebnikov AI; Shibinska MO; Levandovskiy IA; Kirpotina LN; Danilenko NV; Quinn MT
Eur J Med Chem; 2019 Dec; 183():111719. PubMed ID: 31563013
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.
Brun MP; Braud E; Angotti D; Mondésert O; Quaranta M; Montes M; Miteva M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2005 Aug; 13(16):4871-9. PubMed ID: 15921913
[TBL] [Abstract][Full Text] [Related]
3. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
Lazo JS; Nemoto K; Pestell KE; Cooley K; Southwick EC; Mitchell DA; Furey W; Gussio R; Zaharevitz DW; Joo B; Wipf P
Mol Pharmacol; 2002 Apr; 61(4):720-8. PubMed ID: 11901209
[TBL] [Abstract][Full Text] [Related]
4. Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties.
Braud E; Goddard ML; Kolb S; Brun MP; Mondésert O; Quaranta M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2008 Oct; 16(19):9040-9. PubMed ID: 18789703
[TBL] [Abstract][Full Text] [Related]
5. Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in vitro biological evaluation, molecular docking and in silico ADME-T studies.
Rostom SAF; Badr MH; Abd El Razik HA; Ashour HMA
Eur J Med Chem; 2017 Oct; 139():263-279. PubMed ID: 28803043
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
Brisson M; Nguyen T; Vogt A; Yalowich J; Giorgianni A; Tobi D; Bahar I; Stephenson CR; Wipf P; Lazo JS
Mol Pharmacol; 2004 Oct; 66(4):824-33. PubMed ID: 15231869
[TBL] [Abstract][Full Text] [Related]
7. Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries.
Jing L; Wu G; Hao X; Olotu FA; Kang D; Chen CH; Lee KH; Soliman MES; Liu X; Song Y; Zhan P
Eur J Med Chem; 2019 Dec; 183():111696. PubMed ID: 31541869
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries.
Tao Y; Hao X; Jing L; Sun L; Cherukupalli S; Liu S; Wu G; Xu S; Zhang X; Shi X; Song Y; Liu X; Zhan P
Bioorg Chem; 2021 Oct; 115():105254. PubMed ID: 34426152
[TBL] [Abstract][Full Text] [Related]
9. Naphthoquinone analogs as inactivators of cdc25 phosphatase.
Ham SW; Park J; Lee SJ; Kim W; Kang K; Choi KH
Bioorg Med Chem Lett; 1998 Sep; 8(18):2507-10. PubMed ID: 9873570
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells.
Nemoto K; Vogt A; Oguri T; Lazo JS
Prostate; 2004 Jan; 58(1):95-102. PubMed ID: 14673957
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel 1,2-bis-quinolinyl-1,4-naphthoquinones: ERK2 inhibition, cytotoxicity and molecular docking studies.
Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Brown AB; Bräse S; Nieger M; Ibrahim MAA
Bioorg Chem; 2018 Dec; 81():700-712. PubMed ID: 30268050
[TBL] [Abstract][Full Text] [Related]
12. Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
Peyregne VP; Kar S; Ham SW; Wang M; Wang Z; Carr BI
Mol Cancer Ther; 2005 Apr; 4(4):595-602. PubMed ID: 15827333
[TBL] [Abstract][Full Text] [Related]
13. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
Lazo JS; Aslan DC; Southwick EC; Cooley KA; Ducruet AP; Joo B; Vogt A; Wipf P
J Med Chem; 2001 Nov; 44(24):4042-9. PubMed ID: 11708908
[TBL] [Abstract][Full Text] [Related]
14. Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK.
Kar S; Wang M; Ham SW; Carr BI
Biochem Pharmacol; 2006 Nov; 72(10):1217-27. PubMed ID: 16930563
[TBL] [Abstract][Full Text] [Related]
15. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
16. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
Johnston PA; Foster CA; Tierno MB; Shun TY; Shinde SN; Paquette WD; Brummond KM; Wipf P; Lazo JS
Assay Drug Dev Technol; 2009 Jun; 7(3):250-65. PubMed ID: 19530895
[TBL] [Abstract][Full Text] [Related]
17. Synthetic small molecule Cdc25 phosphatases inhibitors.
Garuti L; Roberti M; Pizzirani D
Curr Med Chem; 2008; 15(6):573-80. PubMed ID: 18336271
[TBL] [Abstract][Full Text] [Related]
18. Effective Pharmacophore for CDC25 Phosphatases Enzyme Inhibitors: Newly Synthesized Bromothiazolopyrimidine Derivatives.
El-Shahat M; Salama MAM; El-Farargy AF; Ali MM; Ahmed DM
Mini Rev Med Chem; 2021; 21(1):118-131. PubMed ID: 32560601
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of new alkylamino- and phenylamino-containing polyfluorinated derivatives of 1,4-naphthoquinone.
Zakharova OD; Ovchinnikova LP; Goryunov LI; Troshkova NM; Shteingarts VD; Nevinsky GA
Eur J Med Chem; 2010 Jun; 45(6):2321-6. PubMed ID: 20189692
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression.
Kabakci Z; Käppeli S; Cantù C; Jensen LD; König C; Toggweiler J; Gentili C; Ribaudo G; Zagotto G; Basler K; Pinna LA; Cozza G; Ferrari S
Sci Rep; 2019 Feb; 9(1):1335. PubMed ID: 30718768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
